Medpace Holdings (MEDP)
NASDAQ:MEDP
Want to see MEDP full AI Analyst Report?
MEDP Stock Chart & Stats
$520.60
$7.21(2.08%)
At close: 4:00 PM EST
$520.60
$7.21(2.08%)
Day’s Range― - ―
52-Week Range$284.48 - $628.92
Previous CloseN/A
Volume64.09K
Average Volume (3M)321.05K
Market Cap
$12.11B
Enterprise Value$11.60B
Total Cash (Recent Filing)$652.68M
Total Debt (Recent Filing)$146.09M
Price to Earnings (P/E)27.6
Beta1.16
Next Earnings
Jul 27, 2026EPS Estimate
3.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)16.24
Shares Outstanding28,559,689
10 Day Avg. Volume374,027
30 Day Avg. Volume321,051
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)35.29
Price to Sales (P/S)6.40
P/FCF Ratio23.76
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue4.33
Enterprise Value/Gross Profit14.90
Enterprise Value/Ebitda20.01
Forecast
1Y Price Target
$460.00Price Target Upside-11.64% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)16.99
Revenue Forecast (FY)$2.77B
Bulls Say, Bears Say
Bulls Say
Artificial Intelligence OpportunityManagement expects artificial intelligence to lower revenue per trial while enabling substantial margin improvements and supporting continued revenue growth.
Backlog ConversionHigher backlog conversion driven by faster-moving metabolic trials supports quicker revenue recognition and helps sustain near-term financial performance.
ValuationAnalyst highlights that the company's valuation has reset to cyclical lows versus the broader market, creating an attractive risk/reward if demand and earnings recover.
Bears Say
Cancellations ImpactElevated cancellations in metabolic trials have reduced forward revenue visibility by eliminating expected future fees even when some interim revenue persists.
Client Concentration RiskA client mix concentrated in small and mid-sized biotech firms increases booking volatility because those companies are more sensitive to capital availability and trial funding.
Revenue Quality ConcernsA revenue beat driven mainly by pass-through items rather than core service fees raises questions about the sustainability and underlying quality of revenue growth.
Medpace Holdings News
MEDP FAQ
What was Medpace Holdings’s price range in the past 12 months?
Medpace Holdings lowest stock price was $284.48 and its highest was $628.91 in the past 12 months.
What is Medpace Holdings’s market cap?
Medpace Holdings’s market cap is $12.11B.
When is Medpace Holdings’s upcoming earnings report date?
Medpace Holdings’s upcoming earnings report date is Jul 27, 2026 which is in 78 days.
How were Medpace Holdings’s earnings last quarter?
Medpace Holdings released its earnings results on Apr 22, 2026. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.921 by $0.359.
Is Medpace Holdings overvalued?
According to Wall Street analysts Medpace Holdings’s price is currently Overvalued.
Does Medpace Holdings pay dividends?
Medpace Holdings does not currently pay dividends.
What is Medpace Holdings’s EPS estimate?
Medpace Holdings’s EPS estimate is 3.98.
How many shares outstanding does Medpace Holdings have?
Medpace Holdings has 28,559,689 shares outstanding.
What happened to Medpace Holdings’s price movement after its last earnings report?
Medpace Holdings reported an EPS of $4.28 in its last earnings report, beating expectations of $3.921. Following the earnings report the stock price went down -22.625%.
Which hedge fund is a major shareholder of Medpace Holdings?
Currently, no hedge funds are holding shares in MEDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medpace Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$460.00 (-11.64% Downside)
$460.00 (-11.64% Downside)
Blogger Sentiment
Bullish
MEDP Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 161.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
75.71%
12-Months-Change
Fundamentals
Return on Equity
120.89%
Trailing 12-Months
Asset Growth
12.24%
Trailing 12-Months
Company Description
Medpace Holdings
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
MEDP Company Deck
MEDP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call showed strong underlying financial performance in Q1 — double-digit revenue and EBITDA growth, healthy cash generation, and a sizable backlog — and management reaffirmed full-year guidance. However, elevated and persistent cancellations, weaker gross bookings/RFPs and a multi-quarter decline in beyond-12-month backlog coverage are meaningful near- to medium-term risks to sequential growth. Management pointed to a good win rate and initiatives to improve pipeline conversion, but the cadence and durability of that improvement remain uncertain.View all MEDP earnings summariesMEDP Revenue Breakdown
98.00% U.S.
2.00% Other
MEDP Stock 12 Month Forecast
Average Price Target
$460.00
▼(-11.64% Downside)
Technical Analysis
Ownership Overview
19.42% Insiders
21.01% Mutual Funds
13.43% Other Institutional Investors
23.83% Public Companies and
Individual Investors